

From reactive to proactive: implementing palliative care for patients with COPD Broese, J.M.C.

## Citation

Broese, J. M. C. (2023, October 17). From reactive to proactive: implementing palliative care for patients with COPD. Retrieved from https://hdl.handle.net/1887/3643947

Version: Publisher's Version

License: Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden

Downloaded

from:

https://hdl.handle.net/1887/3643947

**Note:** To cite this publication please use the final published version (if applicable).



Effectiveness and implementation of palliative care interventions for patients with chronic obstructive pulmonary disease: A systematic review

Johanna MC Broese Albert H de Heij Daisy JA Janssen Julia A Skora Huib AM Kerstjens Niels H Chavannes Yvonne Engels Rianne MJJ van der Kleij

Palliat Med 2021 Vol. 35 Issue 3 Pages 486-502

### **Abstract**

### **Background**

Although guidelines recommend palliative care for patients with chronic obstructive pulmonary disease, there is little evidence for the effectiveness of palliative care interventions for this patient group specifically.

#### Aim

To describe the characteristics of palliative care interventions for patients with COPD and their informal caregivers and review the available evidence on effectiveness and implementation outcomes.

### Design

Systematic review and narrative synthesis (PROSPERO CRD42017079962).

#### **Data sources**

Seven databases were searched for articles reporting on multi-component palliative care interventions for study populations containing ≥30% patients with COPD. Quantitative as well as qualitative and mixed-method studies were included. Intervention characteristics, effect outcomes, implementation outcomes and barriers and facilitators for successful implementation were extracted and synthesized qualitatively.

#### Results

Thirty-one articles reporting on twenty unique interventions were included. Only four interventions (20%) were evaluated in an adequately powered controlled trial. Most interventions comprised of longitudinal palliative care, including care coordination and comprehensive needs assessments. Results on effectiveness were mixed and inconclusive. The feasibility level varied and was context-dependent. Acceptability of the interventions was high; having someone to call for support and education about breathlessness were most valued characteristics. Most frequently named barriers were uncertainty about the timing of referral due to the unpredictable disease trajectory (referrers), time availability (providers) and accessibility (patients).

#### Conclusion

Little high-quality evidence is yet available on the effectiveness and implementation of palliative care interventions for patients with COPD. There is a need for well-conducted effectiveness studies and adequate process evaluations using standardized methodologies to create higher-level evidence and inform successful implementation.

**Keywords**: Chronic obstructive pulmonary disease, palliative care, breathlessness, quality of life, systematic review

### What is already known about the topic?

Patients with advanced COPD have a high symptom burden and impaired quality of life. Although guidelines recommend palliative care for patients with COPD, implementation remains often challenging and an up-to-date overview of the evidence on its effectiveness is lacking.

Effectiveness and implementation of palliative care interventions

### What this paper adds?

- This review provides a comprehensive overview of evidence on the effectiveness and implementation of palliative care interventions targeting patients with COPD and their informal caregivers.
- Within different care contexts, short-term palliative care assessments as well
  as longitudinal palliative care interventions with care coordination have been
  implemented. Highly valued intervention characteristics are the direct access to a
  professional for support, an ongoing relationship with a professional and education
  about breathlessness.
- Few interventions have been evaluated using a controlled study design. Positive
  effects were found on outcomes related to advance care planning and perceived
  symptom control and self-management, but not on health outcomes.

### Implications for practice, theory or policy

- Research on palliative care in COPD should focus on what is important to patients with end-stage COPD and their informal caregivers. More knowledge is needed on which outcomes best reflect their needs.
- Controlled studies with sufficient power are needed to evaluate the effectiveness of palliative care on patients with COPD and their informal caregivers.

## Introduction

Chronic Obstructive Pulmonary Disease (COPD) is the third leading cause of death worldwide.¹ Patients suffering from end-stage COPD experience severe breathlessness and other debilitating symptoms such as fatigue, pain, anxiety and depression, leading to poor quality of life and emphasizing the need for adequate palliative care.² Palliative care aims to improve the quality of life of patients with a life-threatening disease and their families by early identification, assessment and treatment of physical, psychological, social and spiritual problems.³ Growing evidence suggests that palliative care, in general, has positive effects on quality of life and can decrease symptom burden in patients with life-limiting illnesses. Additionally, it can improve patient and informal caregiver satisfaction with care and reduces healthcare utilization.⁴ However, for patients with advanced COPD, palliative care is not yet part of standard care, and discussions about goals of (end-of-life) care rarely take place, or only late in the disease course.⁵ As a consequence, their severe symptoms remain undertreated, and a large proportion of this patient group inadvertently dies in the hospital. <sup>6,7</sup> Moreover, the long disease course with declining functional capacity affects their informal caregivers.8

Implementing palliative care for patients with COPD is challenging. Due to the unpredictable disease trajectory, healthcare professionals struggle to determine when to refer patients for specialized palliative care. Further, palliative care for patients with COPD needs to be differently organized than for oncological patients because it demands integration of palliative care and disease-oriented care until the end-of-life. The implementation of palliative care in COPD-care is further complicated as professionals must perform actions they are not used to, such as discussing holistic needs and end-of-life topics.

Although guidelines recommend palliative care for patients with COPD, there is little evidence for the effectiveness of palliative care interventions for this patient group specifically. <sup>12</sup> In previous systematic reviews, the vast majority of the interventions described were designed for patients with cancer <sup>4, 13, 14</sup> or focused on a single intervention component only. <sup>15-17</sup> Research on the effectiveness of interventions that integrate multiple components of palliative care for patients with COPD is still lacking. <sup>18</sup> Further, it remains unclear how palliative care can be organized for this patient group and what are requirements for successful implementation. Finally, no reviews have included intervention outcomes at the level of the informal caregiver and professional.

To guide future palliative care provision for patients with COPD and to identify gaps in the current evidence-base, we, therefore, aimed to review multi-component palliative care interventions targeting patients with advanced COPD and their informal caregivers. Specifically, we aimed to:

1. Synthesize the characteristics of multi-component palliative care interventions targeting patients with COPD and their informal caregivers;

- 2. Review the evidence for the effectiveness of those interventions on patient, informal caregiver and healthcare professional outcomes;
- 3. Review the evidence on implementation outcomes and barriers and facilitators of implementation.

## **Methods**

The protocol of this systematic review has been registered in the international Prospective Register of Systematic Reviews (PROSPERO) database (ID: CRD42017079962). We used the Cochrane Handbook for Systematic Reviews of Interventions to perform the review, and followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement for reporting.

### Literature search

The electronic databases MEDLINE, Embase, Web of Science, COCHRANE Library, PsycINFO, CENTRAL and Emcare were searched for eligible studies. In the search strategy, we combined a broad range of synonyms of the search terms "COPD" and "palliative care" (Supplementary table 1). Articles that were published between 1 January 1990 and 9 June 2020 were screened for inclusion, without language restrictions. We searched for other potentially relevant studies by screening the reference lists and citations of included studies.

## **Study selection**

Articles reporting on primary research data of multi-component palliative care interventions targeting patients with COPD were included. The intervention described in the article needed to be referred to as a palliative care or end-of-life care intervention, program or approach. We defined a multi-component intervention as an intervention comprising multiple components which interact to produce change, following the complex intervention definition of the Medical Research Council.<sup>19</sup> Interventions focusing only on a single component (such as advance care planning or opioids for breathlessness) were excluded. If the study population was mixed, articles were included if at least 30% of the study population suffered from COPD. Case reports and non-primary research data, such as reviews, editorials, conference abstracts and books were excluded. We also included uncontrolled before-and-after studies, qualitative and mixedmethod studies, as this 1) reflects the most frequent type of studies performed and provides a comprehensive overview of all available evidence, and 2) because we wanted to gain in-depth insight into mechanisms or elements contributing most to intervention effectiveness and successful implementation. Title and abstract screening and subsequent full-text screening was done by two reviewers independently (J.B., and J.S. or A.H.). In case of any incongruences, the in- or exclusion of an article was discussed until consensus was reached. In case of doubt, a third researcher (R.K.) was consulted.

### **Data extraction**

Data on design, participants, intervention characteristics and all reported outcomes at patient, informal caregiver and healthcare professional level were extracted using a piloted extraction form. If necessary and possible, additional data was derived from published study protocols or supplementary documents, or requested from the authors. Data extraction of the included articles was done by two reviewers independently (J.B. as first reviewer for all articles and A.H., D.J., Y.E. or R.K. as a second reviewer). Any incongruencies were discussed until consensus was reached. Implementation outcomes and barriers and facilitators for implementation were extracted by one reviewer (J.B.) and discussed with a second reviewer who has great expertise in implementation (R.K.).

## **Quality appraisal**

Quality appraisal was performed by two reviewers (J.B. and A.H.) independently, using the Mixed Methods Appraisal Tool.<sup>20</sup> After two screening questions, each study is appraised by rating appraisal criteria for the corresponding category. Any discrepancies in the quality appraisal were resolved by discussion, and if needed, a third reviewer (R.K.) was consulted. To compare study quality, we assigned four stars to a study when 75 to 100% of the criteria were positively rated (high quality), three stars for 50-75% (moderate quality), two stars for 25-50% (low quality) and one star for 0-25% (very low quality).

### **Data analysis**

Data were analysed using narrative synthesis.<sup>21</sup> Study characteristics were summarized in terms of country, design, objective, study participants, inclusion strategy, intervention and organizational characteristics and outcomes. The intervention components were categorized according to twelve palliative care domains based on the Dutch Quality Framework Palliative care, 12 Clinical Practice Guidelines for Quality Palliative Care22 and Quality standard End of life care for adults.<sup>23</sup> The operationalization of domains is described in Supplementary table 2. Outcomes were classified into three categories: outcomes at patient, informal caregiver, and healthcare professional level. Quantitative results reported in studies in which no statistical testing was performed, were disregarded. The text in articles reporting on qualitative outcomes was coded phrase by phrase after which common themes were identified.<sup>24</sup> We categorized implementation outcomes following the proposed terminology and operationalization of Proctor et al<sup>25</sup> (see Supplementary table 3). According to Proctor et al, implementation outcomes are defined as "the effects of deliberate and purposive actions to implement new treatments, practices, and services" <sup>25</sup> (page 65). Process outcomes reflecting trial feasibility (and not intervention feasibility) were not evaluated. Barriers and facilitators to implementation of palliative care interventions were categorized using the framework of Fleuren et al.26 This instrument consists of 29 determinants in four categories: determinants associated with the (a) innovation, (b) adopting person, (c) organization and (d) socio-political context. We extracted determinants for three types of users: referrers (professionals who refer patients to the palliative care intervention),

providers (professionals who provide the intervention) and patients (individuals who receive the intervention). If needed, determinants of the Consolidated Framework for Implementation Research<sup>27</sup> or newly defined determinants were added inductively. The codebook used is available in Supplementary table 4.

### **Results**

The database search yielded 5621 unique records. In total, 166 articles were excluded based on publication date. Next, we excluded 5310 articles based on title-abstract screening. The full-text versions of the remaining 145 articles were assessed for eligibility. Twenty-three of them met inclusion criteria. Screening of references and citations of included articles identified eight additional articles. A flow diagram of the study selection is displayed in figure 1. Finally, 31 articles were included that reported on 20 unique palliative care interventions; six interventions were evaluated in more than one article.




Figure 1. PRISMA flow diagram of the study selection process.

### **Study characteristics**

Chapter 3

Characteristics of included studies and interventions are summarized in Table 1. All studies took place in western countries, of which most in the USA (n=5) and the United Kingdom (n=4). Three RCTs<sup>28-30</sup>, two non-randomized controlled trials<sup>31-33</sup>, seven uncontrolled before-and-after studies<sup>34-41</sup>, six qualitative studies<sup>42-47</sup>, one non-comparative study<sup>48</sup> and ten pilot/feasibility studies<sup>37, 49-54</sup> <sup>55-57</sup> were included. The study design of one article was unclear. <sup>58</sup> Two articles reported on the same study and were collated. <sup>32, 33</sup> Five quantitative studies <sup>30, 33, 35, 41, 48</sup> and six pilot/feasibility studies <sup>37, 50-52, 54, 55</sup> also included qualitative data. Eighteen studies (60%) focused specifically on COPD. Other studies focussed on refractory breathlessness<sup>29, 30, 38, 42, 43, 54</sup> or also included patients with heart failure<sup>28, 34, 44, 58</sup> or heart failure and cancer<sup>33, 45</sup>. Sample sizes in quantitative studies ranged from 13 to 228 patients and in qualitative (sub)studies from 6 to 78 patients. The mean age of study populations ranged between 63 and 76 years.

### **Intervention characteristics**

Half of the interventions were developed based on literature according to the description in the article; two were based on specific guidelines. Thirteen of the twenty interventions comprised of longitudinal care in which there was regular contact of a nurse with patients via home visits<sup>28, 34-36, 39, 44, 55, 57</sup>, outpatient visits<sup>31, 33, 47</sup> or a combination of both<sup>38</sup>. Vitacca et al. included telemonitoring.<sup>56</sup> The majority of longitudinal care interventions included symptom management and needs assessments, disease education and self-management, advance care planning and care coordination. Informal caregiver support was incorporated in eight interventions and consisted of caregiver education.<sup>28, 30, 33, 35, 38</sup> nurse assessment of needs<sup>28, 33, 44, 55, 57</sup>, invitation to support groups<sup>33</sup> and respite care<sup>38</sup> and was unspecified in lupati et al.<sup>36</sup> Most were organized by a community care organization, such as a hospice care service or home service. Six other interventions comprised of one comprehensive needs assessment with a short follow up.<sup>29, 30,</sup> <sup>37,52-54</sup> They included one to four home visits and/or outpatient visits and were mostly organized by pulmonary care and palliative care departments. Four interventions specifically focussed on the management of breathlessness<sup>29, 30, 37, 54</sup> and comprised of various pharmacological and non-pharmacological interventions to address breathlessness and how to cope with this symptom. Farguhar et al. also included informal caregiver education. Lastly, one intervention was a 6-week multidisciplinary geriatric rehabilitation program in a specialist nursing facility. Patients in need of palliative care were proactively identified by six interventions, by screening patients during hospitalization for acute exacerbation<sup>31, 40, 52</sup> or by using a computerized screening program based on diagnosis and hospitalizations or measures of disease severity.<sup>33, 34</sup> In most other cases, patients were referred to the service by healthcare professionals.

 Table 1. Description of included studies and palliative care interventions.

וורומתכת אנחמוכא	<u> </u>		mer vention describing	acı ibrioni						
Author (year)	Study design	Sample size	Intervention name; Development	Country	Coordinating organization	Intervention	Conditions	Healthcare professionals	Contacts	Duration (months)
Aiken <sup>28</sup> I ockhart <sup>58</sup>	RCT Harlear	190 patients	Phoenix care program; N.S.	USA	Hospice care service	Home-based case management focused on disease and symptom management,	сорр, нғ	N Other team members: P, SW, SPI	Combined home visits and phone calls	3 – 18, until death or referral to hospice
		5				patient and caregiver education, social and psychological support and preparation for end of life through discussing legal documents				
Bove <sup>47</sup>	O	7 pulmonary	CAPTAIN;	Denmark	Hospital	A new outpatient	COPD	NR, PM	Outpatient	Until death
		pulmono-	literature		pulmonology	patients are assigned			depending	
		municipal				hoc consultations			needs and	
		ope in				patient's needs and annual advance care			advance care	
Bove <sup>46</sup>	o	10 patients				planning discussions			D	
Buckingham <sup>52</sup>	RCT +Q (pilot/	RCT: 32 patients	HELP-COPD program: based	λ	Hospital (pulmonology	Holistic assessment of physical.	COPD	NR	1 home visit, 3 phone calls	9
	llity)	Q: 8 patients, 3 carers and	on Systematic literature		department)	psychological, social and spiritual needs			for follow up	
		28 SWs or HCPs	review (sten 1 MRC			4 weeks after an hospital admission				
		) -	framework)			for an acute exacerbation				
Duenk³¹	CCT	228 patients	PROLONG study; based	Netherlands		Proactive palliative care plan and	COPD	PCN or PCP	In- or outpatient	12, or until death
			on national guideline Palliative care		palliative care team)	montniy meetings with specialized palliative care team		cooperation with PM	consultation and monthly meetings	
			in COPD			trained in palliative care in COPD			outpatient or via phone	

Median=6	_				_
1 to 9 home visits per month based on clinical judgement	1 home assessment, 3 outpatient visits, phone call for questions				1 home visit and 2 outpatient visits
N, OT and SW Other team members: D, GER	PT and PCP				PM, PCP, PT, OT Other team members: SW
COPD, HF	refractory breathless -ness				refractory breathless- ness
Home care including symptom management and advance directive discussions, assessing nutrition, nursing needs, spiritual/religious concerns, depression, community support services, financial matters, family communication, functional status, mobility and home safety	Assessment of breathlessness and symptom management including a hand-held fan, education, learning an anxiety-reduction technique	and a mindfulness meditation CD, deciding a	management plan, designing an exercise program, and assessing the carer's needs.		Multi-professional service with holistic assessment and optimization of disease-management with a breathlessness pack including information,
Home care	Palliative care department in a tertiary referral and cancer centre				University hospital (respiratory medicine and palliative care)
NSA	n Ck				Ž
Home-based Primary care program + non- VA community hospice agency; N.S.	Breathlessness Intervention Service; Based on Iterature review (step 1 MRC framework)				Breathlessness Support Service; based on previous studies on holistic preathlessness services,
43 patients	RCT: 87 patients, 57 carers Q: 78 patients or patient- carer dyads	RCT and Q: 13 patients, 12 carers	13 patients a	10 patients, 9 carers, 4 GPs, nurses	105 patients
₩	RCT +Q	RCT +Q (trial feasibility)	BA +Q (pilot/ feasibility)	O	RCT
Edes <sup>34</sup>	Farquhar <sup>30</sup>	Farquhar <sup>49</sup>	Farquhar <sup>so</sup>	Booth <sup>42</sup>	Higginson <sup>29</sup>

Table 1. Continued

64

Included studies	dies		Intervention description	scription						
Author (year)	Study design Sample size	Sample size	Intervention name; Development	Country	Coordinating organization	Intervention	Conditions	Healthcare professionals	Contacts	Duration (months)
Higginson <sup>29</sup>	RCT	105 patients	systematic literature review and local stakeholders consultation			management and pacing guidance, a hand-held fan or water spray, and a short mantra to help breathing and				
Reilly <sup>43</sup>	o	25 patients				relaxation during crises and a crisis plan				
Horton <sup>53</sup>	BA (pilot/ feasibility)	30 patients, 18 carers	COPD IMPACT study; based on existing needs assessment and adapted existing education material	Canada	Hospice care service	Education on disease self management and end-of-life issues and comprehensive palliative care consultation and treatment plan	СОРБ	N, RT Other team members: P	1 home visit, weekly phone contact and follow up visits if needed	4
lupati <sup>36</sup>	BA	73 patients	GP Led and Hospice Led community program; N.S.	New Zealand	Hospice care service	GP led program: case management and 24-h access to hospice nursing advice and visits. Hospice led program: 24-h access to nursing and medical team advice and consultations	COPD	PCP, PCN, GP	Hospice doctor's visits and nurses visits. Inpatient hospice care if needed. Phone advice if needed.	Undefined
Janssens <sup>57</sup>	RCT (pilot/ feasibility)	49 patients	Early palliative care; based on literature review	Switzerland	Community ambulatory palliative care team	Monthly home visits for symptom assessment and management, disease education, advance care planning, support of relatives, social and spiritual support, care coordination	ООРО	PCN and PCP	Monthly home visits	2

	Undefined		1.5
	Home visits L	3 outpatients 3 visits, phone call weekly	2 outpatient 1 Visits in clinic
	N N N N N N N N N N N N N N N N N N N	N Other team members: PM	NR, PM
	СОРБ, НЕ	СОРБ	refractory breathless- ness, non malignant
as relaxation, reflexology, massages	Community service providing palliative care assessment and care planning, information on disease process, treatment, medication, local and national aservices, advice on symptom control and psychological support for patient/carer	Pharmacologic and non-pharmacologic interventions for dyspnea, anxiety, and depression, including pursed-lip breathing, activity pacing, fan, morphine, relaxation exercises, anxiolytics, psychotherapy referral and antidepressants	Integrated respiratory and palliative care service providing individualized breathlessness plan, information leaflets, breathlessness education and hand-
	Primary care service	Tertiary care pulmonary specialty medical centre	Hospital (respiratory and palliative care)
	n n	USA	Australia
	EOLC-LTC service; N.S.	Advance practice nurse- delivered palliative care intervention; based on existing scientific evidence for intervention	Advanced Lung Disease Service - short term; N.S.
	6 patients, 6 carers, HCPs, stakeholders	BA: 15 patients Q: 13 patients	BA: 26 patients Q: 9 patients
	σ	BA +Q (pilot/ feasibility)	BA +Q (pilot/ feasibility)
	Johnston⁴⁴	Long <sup>37</sup>	Qian <sup>54</sup>

Chapter 3

 Table 1. Continued

 Included studies

66

inciuaea stuales	ales		intervention description	scription						
Author (year)	Study design	Study design Sample size	Intervention name; Development	Country	Coordinating organization	Intervention	Conditions	Healthcare professionals	Contacts	Duration (months)
Rabow <sup>33</sup> / Rabow <sup>45</sup>	٥	CCT: 90 patients Q: 50 patients S0 patients	Care Team; N.S	USA	General medicine practice	Outpatient comprehensive palliative care consultation service including assessment of needs and end- of-life orientation, education, and services	COPD, HF,	SW, N, SPI, P, ADV Other team members: PSY, PHA, ART	At start, at 6 and 12 months outpatient visit. Home visits by volunteers each month, phone contact each week.	12
Rocker <sup>35</sup>	BA +Q	BA: 257 patients Q: 18 patients	INSPIRED COPD Outreach program; reported to be evidence based not further specified	Canada	Community	Hospital-to-home COPD care focused on improved care transitions, patient and family education and self-management,	COPD	RT, SPI Other team members: SW, P, N	4 home visits, access to phone support	3-6
Gillis <sup>51</sup>	BA +Q (pilot/ feasibility)	BA: 15 patients Q: 14 patients				action plans for exacerbation psychosocial and				
Rocker <sup>41</sup>	BA +Q	19 healthcare professional teams				spiritual needs assessment and support and advance care planning				
Verma⁴ <sup>8</sup>	Non- comparative +Q	19 healthcare professional teams								
Scheerens <sup>55</sup>	RCT +Q (pilot/ feasibility)	RCT: 39 Q: 9 patients, 4 ICGs, 10 GPs, 5 PMs, 4 home PCNs	Early Integrated Palliative Homecare; based on explorative literature review, expert	Belgium	Home care	Palliative homecare including leaflets on coping mechanisms, protocol on symptom management and support, a care plan and action plan	СОРБ	PCN	Monthly home visits	9

			0-1 MRC framework)							
Smallwood <sup>38</sup>	ВА	171 patients	Advanced Lung Disease Service - long term; N.S.	Australia	Hospital (respiratory and palliative care)	Integrated respiratory and palliative care breathless service providing ness, non long-term holistic care, individualised symptom management and disease optimisation, self-management education, routine discussion of goals of care and breathlessness management including breathling techniques, activity pacing and handheld fan	refractory breathless- ness, non malignant	NR, PM, PSY, PCP Other team members: EDP, GER, PSY	Clinic or home visits and phone support	Depending on patient's needs (median 15)
Steinel <sup>39</sup>	ВА	30 patients	Pulmonary Disease Management Program; N.S.	USA	Home healthcare service	Long-term and continuous home healthcare by pulmonary specialty team, including a palliative care model to manage dyspnoea, loss of functional capacity and emotional suffering	COPD	N Ω	Home care until death, access to a team member at all times	24, or until death
Van Dam <sup>40</sup>	ВА	61 patients	GR-COPD program; based on national and international guidelines on pulmonary pulmonary and palliation and palliative care	Netherlands	Specialized nursing facility	Tailored geriatric rehabilitation programme including inhalation techniques, smoking cessation, control of symptoms, physiotherapy, occupational therapy, nutritional	COPD	GER, N, PT, PSY, OT, SLP, D, SW	6-week inpatient rehabilitation program. 18-22 h of nursing care and 4 h of individual therapy per week	1.5 (median 35 days)

Included studies	ndies		Intervention description	scription						
Author (year)	Study design	Sample size	Intervention name; Development	Country	Coordinating organization	Intervention	Conditions	Healthcare professionals	Contacts	Duration (months)
						status, psychosocial intervention aimed at depression, anxiety or adverse coping strategies, self-management strategies and peer support contact, spiritual needs, advance care planning				
Vitacca <sup>56</sup>	BA (pilot/feasibility)	10 patients	Tele-assisted palliative homecare; based on previous studies on tele-assisted care	Italy	Hospital (respiratory rehabilitation unit)	An inpatient advance care planning talk and post-discharge pulse oximetry recording and regular telephone monitoring including palliative care assessments	СОРО	Z.	1 inpatient talk and weekly telephone monitoring after discharge and monthly palliative assessment	9

<sup>&</sup>lt;sup>a</sup> Farquhar et al. (2009) and Farquhar et al. (2010) report on the same study population, but each uses a different study design and thus were considered as separate studies.

Abbreviations: ADV, volunteer patient advocate; ART, art therapist; BA, before and after study; CCT, non-randomized clinical controlled trial; COPD, chronic obstructive pulmonary disease; D, dietitian; EDP, emergency department physician; GER, geriatric medicine physician; GP, general practitioner; HCP, Healthcare professional; HF, heart failure; N.S., not stated; N, nurse, nurse practitioner, advanced practice nurse; NR, respiratory nurse specialist or nurse trained in respiratory medicine, OT, occupational therapist; P, physician undefined; PCN, palliative care nurse; PCP, palliative care physician; PHA, pharmacist; PM, pulmonologist; PSY, psychologist; PT, physiotherapist; Q, qualitative study; RCT, randomized controlled trial; RT, respiratory therapist; SLP speech and language pathologist; SPI, spiritual care practitioner, chaplain or pastoral counsellor; SW, social worker; UK, United Kingdom; USA, United States of America.

 Table 2. Addressed domains by palliative care interventions for patients with COPD.

Intervention (references)	Structure & process	ocess					Dimensions	ions			End of life	
	Identification Advance Care Individual Informal Planning care plan care given support	Advance Care Planning	Individual care plan	Informal care giver support	Interdisciplinary Care care	/ Care coordination		Physical Psychological Social Spiritual	Social	Spiritual	End of life Be care ca	Bereavement care
Aiken et al. <sup>28, 58</sup>		>		>	>	>	>	>	>	>		
Bove et al. <sup>47</sup>		>				>	>	>				
Buckingham et al. 52	>		>				>	>	>	>		
Duenk et al.³¹	>	>	>		>		>	>	>	>		
Edes et al.³⁴	>	>			>	>	>		>	>		
Farquhar et al. <sup>30, 42, 49, 50</sup>				>	>		>	>	>			
Higginson et al. <sup>29, 43</sup>					>		>	>		>		
Horton et al. <sup>53</sup>		>	>		>	>	>	>	>	>		
lupati et al.³⁵		>		>		>	>	>	>	>	>	
Janssens et al. <sup>57</sup>		>		>	٠.	>	>	>	>	>		
Johnston et al. <sup>44</sup>		>		>		٠.	>	>				
Long et al. <sup>37</sup>							>	>				
Qian et al. <sup>54</sup>					>		>	>				
Rabow et al. <sup>32, 33, 45</sup>	>	>		>	>	>	>	>	>	>		
Rocker et al. <sup>35, 41, 48,51</sup>	>	>		>	>	>	>	>	>	>		
Scheerens et al. <sup>55</sup>		>	>	>		>	>	>	>	>		
Smallwood et al.38		>		>	>	>	>	>	>		>	
Steinel et al.³9						٠.	>	>				
Van Dam et al. <sup>40</sup>	>	>	>		>		>	>	>	>		
Vitacca et al. <sup>56</sup>		>				۲.	>	>	>	>		

## **Quality appraisal**

Ratings of the criteria of the Mixed Methods Appraisal Tool per study are provided in Supplementary table 5. Quality of the studies was related to the study design used. All three RCTs were of high quality; non-randomized controlled trials and qualitative studies were of moderate to high quality; study quality of uncontrolled studies ranged from very low to moderate. The quality of pilot/feasibility studies varied from low to high. Two articles were not appraised as they did not pass the screening questions. <sup>35, 58</sup> The following reasons most frequently contributed to a negative rating: lack of information on intervention adherence in controlled trials, insufficient use of quotations that supported interpretations of results in qualitative studies, and absence of adjusting for confounding in uncontrolled studies. In studies with both a quantitative and qualitative component, there often was poor integration of the two components.

### **Quantitative outcomes**

Quantitative results are summarized in Table 3. The most frequently evaluated outcomes were acute healthcare use, health-related quality of life and psychological outcomes. Four out of seven controlled studies reported a primary outcome: mastery of breathlessness<sup>29</sup>, distress due to breathlessness<sup>30</sup>, health-related quality of life<sup>31</sup> and pain<sup>32</sup>. Janssens et al. had initially planned to measure acute healthcare use as primary outcome.<sup>57</sup> However, they did not reach sufficient power to do so due to severe recruitment issues. One study found a statistically significant positive effect on its primary outcome; Higginson et al. reported a difference in mastery of breathlessness between intervention and control group of 0.58 (0.01 to 1.15).

Outcomes at patient level

Quality of life – Health-related quality of life was assessed in ten studies, <sup>28, 29, 31, 32, 35, 37, 40,</sup> <sup>55-57</sup> using seven different measurement instruments. Duenk et al. set health-related quality of life as their primary outcome. Their study and that of Aiken et al. found significant differences between the intervention and control group on specific subscales but not on the total scale. <sup>28,</sup> <sup>31</sup> The uncontrolled study of Van Dam et al. reported an improvement on health-related quality of life: <sup>40</sup> all other studies found no differences. <sup>28, 29, 31, 32, 35, 37</sup>

Breathlessness – In two RCTs evaluating holistic breathlessness services, <sup>29,30</sup> intervention patients showed higher levels of mastery of breathlessness, but only one study found a statistically significant difference. <sup>29</sup> No difference was found on distress due to breathlessness in one RCT. <sup>30</sup> In the study of Rabow et al, intervention patients reported a lower degree of breathlessness interference with daily activities and limitations in daily life compared to control patients. <sup>32</sup> Two other controlled studies did not find an effect on breathlessness intensity. <sup>29,37</sup>

*Anxiety and depression* – Rabow et al. reported reduced anxiety in intervention patients, but no change in depression.<sup>32</sup> Eight other studies found no significant differences.<sup>29-31, 35, 37, 55-57</sup>

Other health-related outcomes – Aiken et al. found lower symptom distress in intervention patients at three months, but not at six months.<sup>28</sup> Further, positive effects were reported for the resumption of activities,<sup>28</sup> sleep quality,<sup>32</sup> functional capacity<sup>40</sup> and nutritional status<sup>40</sup>.

*Spiritual Well-being / Hope* – In the study of Rabow et al., intervention patients reported higher overall spiritual well-being than control patients.<sup>32</sup> One study evaluating hope found no difference after the intervention.<sup>35</sup>

Self-management – The study of Aiken et al. revealed an improvement in illness self-management and awareness of resources, at specific time points.<sup>28</sup> Rocker et al. found a positive result on the quality of preparation for self-care<sup>35, 41</sup> and need for information after program participation.<sup>41</sup>

Health care use – Mixed results were found regarding unplanned health care use. Controlled studies showed no effect on the number of emergency department visits or hospitalizations. <sup>28, 31, 32, 55, 57</sup> Uncontrolled studies revealed reduction in the number of emergency department visits and hospitalizations. <sup>35, 38, 39 34-36, 39</sup> One pilot RCT reported more hospitalizations in the intervention group than the usual care group. <sup>55</sup> A comparison of deceased intervention patients with other decedents showed a shorter median length of stay at the Intensive Care Unit. <sup>35</sup>

Advance care planning – Five studies found that, for intervention patients, a personal directive and advance care planning choices were more often documented,<sup>28,31,35,57</sup> and funeral arrangements were more likely to be completed.<sup>32</sup>

*Site of death* – One controlled study examining site of death found no differences between intervention and control group.<sup>32</sup>

Satisfaction with care – Two controlled studies found no difference between intervention and control group regarding satisfaction with care; <sup>32, 55</sup> the uncontrolled study of Edes et al. reported an improvement.<sup>34</sup>

#### Outcomes at informal caregiver level

Only one study examined outcomes at informal caregiver level and found no differences in caregiver distress due to patient breathlessness, nor on anxiety and depression between the intervention and control group.<sup>30</sup>

#### Outcomes at healthcare professionals' level

Outcomes at professional level were only assessed in one uncontrolled study. A positive effect on several skills regarding quality improvement and implementation was reported.<sup>48</sup>

#### Costs

Two controlled studies found no difference in healthcare costs of intervention patients,<sup>30, 32</sup> of which one also evaluated cost-effectiveness and found high costs gained per quality-adjusted life-year.<sup>30</sup> Three uncontrolled studies reported lower healthcare costs per patient in the period after the start of the intervention.<sup>34, 35, 39</sup>

### **Qualitative outcomes**

Qualitative outcomes were derived from interviews in fourteen qualitative (sub)studies.<sup>30, 35, 37, 41-48, 52, 54, 55</sup> In most studies, patients reported improved self-confidence to manage symptoms<sup>30, 35, 37, 41, 43, 44, 46</sup> and positive psychological effects.<sup>30, 35, 37, 43, 45, 52</sup> Besides, in some cases, hospitalization was prevented due to earlier diagnosis and treatment.<sup>44-46</sup> Regarding informal caregivers, increased confidence was reported because they knew how they could help their relatives with breathlessness.<sup>30, 42</sup> Regarding healthcare professionals, nurses providing palliative care got more insight in and understanding of the suffering of patients with COPD and complexities around COPD-care.<sup>47, 48</sup>

**Table 3.** Summary of quantitative outcomes and results at the level of the patient, informal caregiver and healthcare professional, and costs. The direction of effects and references are shown.

	Study des	sign			
	RCT	Pilot RCT	ССТ	ВА	Pilot BA
Patient					
Quality of life	<b>O</b> 28 O29	057 055	O31 O32	●40 O35	037 056
Breathlessness intensity	O29		●32		O37
Breathlessness affect	●29 O30				
Anxiety / Depression	O29 O30	057 055	<b>O</b> 32 O31	O35	037056
Other health-related outcomes	<b>O</b> 28 O29	057055	<b>O</b> 32	●40	O56
Spiritual Wellbeing/Hope			●32	O35	
Self management	<b>0</b> 28			●35 ●41	
ED visits	O28	057	O32	●35 ●38 ●39	
Hospital admissions		○57 ◎55	O31 O32	●34 ●35 ●36 ●39 ○38	
Advance care planning	<b>0</b> 28	●57	●31 ●32	●35	
Site of death			O32		
Satisfaction with care		O55	O32	●34	
Informal caregiver					
Caregiver distress due to patient breathlessness	O30				
Anxiety/Depression	O30				
Healthcare professional					
Team skills acquisition				●41	
Costs	O30		O32	●34 ●35 ●39	

The direction of effects and references are shown.

- Positive effect—if, after statistical analysis, a significant effect was reported favouring the intervention group (RCT and non-randomized controlled studies), or positive effect between baseline and after intervention (before-and-after studies).
- O = No statistically significant effect—if, after statistical analysis, no significant effect was reported.
- Mixed effects—if in that specific outcome category, more than one outcome was reported with both positive and no effects.
- ⊗ = Negative effect—if, after statistical analysis, a significant effect was reported favouring the control group (RCT and non-randomized controlled studies), or a negative effect between baseline and after intervention (before-and-after studies).

BA: before and after study; CCT: non-randomized clinical controlled trial; ED: emergency department; RCT: randomized controlled trial.

## Implementation outcomes and barriers and facilitators

#### Implementation outcomes

In the included studies, acceptability and feasibility were the most frequently assessed implementation outcomes. Supplementary table 3 provides the operationalization of implementation outcomes. Acceptability was mostly assessed by interviewing patients, <sup>42, 44, 45, 52, 54, 46, 55</sup> informal caregivers and referring healthcare professionals, <sup>42, 44, 52</sup> but also by using a questionnaire among participants <sup>43</sup> or by collecting patient stories anecdotally. <sup>58</sup> All studies reported that patients, informal caregivers and healthcare professionals valued the palliative care intervention. Components of the interventions that were highly valued included being listened to and direct access to a professional for support, <sup>30, 35, 42, 44, 46, 50, 55</sup>, continuity of the relationship<sup>44, 46</sup> and education about breathlessness management. <sup>30, 35, 42, 43, 50, 55</sup> Specifically regarding breathlessness, non-pharmacological interventions such as a hand-held fan and

**Table 4.** Barriers and facilitators for implementation (determinants) of referrers, providers and patients that were present in ≥3 studies.

User type Determinant	Category	Direction (references)	Example (reference)Referrer
Referrer			
Relevance for patient	Innovation	Facilitator <sup>33,42,52</sup>	The innovation was perceived as helpful for patients, which motivated professionals to refer patients. <sup>52</sup>
Awareness of content of innovation	Adopting person	Barrier <sup>44,51,58</sup>	Referrers were not aware that the service existed, which hampered referral of patients to the innovation. <sup>44</sup>
Disease-specific characteristics	Adopting person	Barrier <sup>33,41,44</sup>	Due to the unpredictable disease trajectory of COPD, referrers found it challenging to determine whether a patient was at the end of life, and thus eligible for referral to the innovation. <sup>44</sup>
Provider			
Time available	Organization	Barrier <sup>33,41,44, 48,51,55</sup>	Staff were unable to dedicate adequate time to the improvement efforts. <sup>33</sup>
Staff capacity	Organization	Facilitator <sup>58</sup> Barrier <sup>33,53</sup>	Consistent staffing by knowledgeable people aware of the program goals contributed to a smooth implementation of the innovation. <sup>58</sup>
Compatibility	Innovation	Facilitator <sup>48</sup> Barrier <sup>44,52</sup>	The timing of the assessment meant that actions overlapped with existing discharge planning. <sup>52</sup>
Financial resources	Organization	Barrier <sup>33,48,53</sup>	Lack of continuous resourcing was a barrier to implementation. <sup>48</sup>
Patient			
Accessibility	Innovation	Barrier <sup>33,37,41,52,53</sup>	Patients experienced difficulty travelling to ambulatory services. 53

breathing techniques were reported to be most helpful.<sup>30, 42, 43, 54, 55</sup> Four studies reported on intervention feasibility using predefined feasibility criteria (e.g. participation rates and completion of the program).<sup>37, 51, 52, 55</sup>

The feasibility level varied and was mostly related to specific intervention context characteristics. For instance, Buckingham et al. encountered fewer actions during assessments than expected due to overlap of their service with existing discharge services. Two studies reported on the completion of program components (fidelity) and one on usefulness (appropriateness) as one of the feasibility criteria. One study evaluating nationwide dissemination of their approach reported on adoption and sustainability; Ifteen of nineteen teams to which the intervention was disseminated incorporated all core interventions of the program and reported sustained improvements.

### Barriers and facilitators for implementation

In ten articles barriers and facilitators for implementation (determinants) of nine different palliative care interventions were reported, 33, 37, 41, 42, 44, 48, 51-53, 55, 58 mostly derived from interviews with referring healthcare professionals and intervention participants. Determinants for referrers, providers and patients that were present in three or more studies are shown in Table 4. All determinants are shown in Supplementary table 6.

## **Discussion**

## **Main findings**

This study reviewed the characteristics of multi-component palliative care interventions for patients with COPD and the available evidence on their effectiveness and implementation, to provide guidance on future palliative care provision and to identify knowledge gaps in the literature. We found that a range of longitudinal and short-term interventions in different care settings has been developed to enhance palliative care provision to patients with COPD. Although the acceptability of the interventions was high among patients, informal caregivers and healthcare professionals, we found only limited evidence on their effectiveness. Quantitative and qualitative data suggest positive effects related to perceived symptom control, self-management and self-confidence. Most frequently named barriers to implementation were uncertainty about the timing of referral due to the unpredictable disease trajectory (referrers), time availability (providers) and accessibility (patients).

## **Interpretation of findings**

The current evidence for multi-component palliative care interventions for patients with COPD is scarce and inconclusive; only four interventions (20%) were evaluated in an adequately powered controlled trial; eight (40%) were evaluated in a pilot or feasibility study only. The assessed outcome measures were heterogenous, and only a few statically significant effects were found.

Six out of seven studies found no positive effect on quality of life. This can be due to several reasons. First, just one study had quality of life set as primary outcome<sup>31</sup> and therefore most studies were not powered for this outcome. Second, it is very likely that interventions affect only certain dimensions of quality of life. As quality of life is often reported as one construct in which physical aspects are prominently present, effects on other dimensions are likely to be missed or underestimated. A positive effect on health status was only seen in an inpatient pulmonary rehabilitation intervention,<sup>40</sup> which may be due to the fact that pulmonary rehabilitation is an intensive intervention and addresses many aspects that are included in health-related quality of life questionnaires. Third, in this patient group with end-stage disease, an improvement in quality of life is possibly hard to achieve because of the progressive nature of the disease. However, in patients with heart failure and cancer, significant effects on quality of life have been found,<sup>4,59</sup> suggesting that there are perhaps other reasons specifically related to COPD or the conducted research.

While no consistent effects were found on health outcomes, advance care planning activities were increased in all studies measuring it.<sup>28, 31, 32, 35, 57</sup> Also, positive effects were reported on quantitative outcomes related to perceived control of breathlessness<sup>29</sup> and self-management.<sup>28, 35</sup> This corresponds with the consistent finding from qualitative studies that after the intervention, patients experienced increased perceived control to manage their symptoms and improved self-confidence<sup>30, 35, 37, 41, 43, 44</sup> due to increased knowledge about their symptoms and the reassurance that support was available if necessary. In line with our findings, a recent meta-analysis on holistic breathlessness interventions found positive effects in the affective domain of breathlessness, but not in level of breathlessness nor quality of life.<sup>14</sup>

Qualitative evidence suggests that longitudinal palliative care interventions prevent emergency department and hospital admissions in some cases due to earlier diagnosis and treatment.<sup>44-46</sup> Quantitative outcomes, however, reveal mixed results. Controlled studies showed no differences between intervention and control group, whereas uncontrolled studies showed a reduction in emergency department and hospital admissions. This difference was also present in healthcare costs, as hospitalizations are responsible for the biggest part of healthcare expenditures:<sup>60</sup> controlled studies reported no statistically significant differences between intervention and usual care patients, and uncontrolled trials showed lower healthcare expenses during the intervention than before. Either way, in line with previous reviews, our results suggest that adding palliative care to usual care does not increase healthcare costs.<sup>4,59</sup>

## Palliative care interventions targeting patients with COPD

Two main intervention types could be identified: short-term palliative care assessments and longitudinal palliative care interventions with care coordination. Both types were regarded as acceptable and helpful to patients with COPD, and were appreciated by referring healthcare professionals since they meet the unaddressed needs of this patient group. Although the high heterogeneity of interventions and outcome measures prevents quantifying which components are most beneficial, qualitative data revealed some characteristics that were consistently

valued and perceived as helpful by patients. This implies that patient and family education on breathlessness management, direct access to a professional for support and an ongoing relationship are essential components to include in future interventions. As these components are rather COPD-specific than palliative care characteristics, it seems that, with sufficient training to healthcare professionals and different care organization, these components could be integrated into regular COPD-care. This would meet the current recommendations of guidelines that integrated palliative care should be provided by generalist or respiratory care professionals, and palliative care specialists become involved only when care needs become complex.<sup>11, 12</sup>

### Implementing palliative care interventions

We identified several factors related to the implementation of palliative care interventions for patients with COPD. First, identifying eligible patients appeared challenging, as is also reflected by the variability in the inclusion criteria and strategies used across studies. The emergency department appeared not to be a feasible recruitment setting for a home-based program,<sup>51</sup> but barriers were also encountered in the ambulatory setting<sup>53</sup> and during computerized screening.<sup>33</sup> Using a natural transition point to identify patients with palliative care needs proactively, such as hospitalization for an acute exacerbation,31,35,40,52 has been recommended in previous research<sup>61</sup> and could possibly facilitate identification of patients. Further, palliative care can best be integrated within existing services to prevent duplication of assessments<sup>52</sup> and to guarantee continuity of care. To facilitate healthcare professionals to provide palliative care, a model that can be adapted to regional needs and providing access to tools showed to be practical.<sup>41</sup> For this vulnerable patient group with high disease burden and low socio-economic status, care needs to be easily accessible, as well in terms of physical distance as financially. This might be resolved by performing assessments during home visits and monitoring patient's needs by phone. Lastly, general organizational conditions such as sufficient time, financial resources and personnel are required for successful implementation.

## Study quality and characteristics

The heterogeneity in methodology and used measurement instruments made quantitative pooling of results impossible. Among included studies, study quality was dependent on study design used: most controlled studies were better conducted than studies with a before-and-after design. As most studies did not report a primary outcome and power calculation, the studies may have been underpowered, causing the effects to be underestimated. On the contrary, four studies evaluated many outcomes without controlling for multiple testing, <sup>28, 32, 35, 41</sup> leading to an increased risk of unjustified positive results. Moreover, a clear difference was found in the direction of effects between controlled and uncontrolled studies, specifically with regard to acute healthcare use and costs. In uncontrolled studies, a positive effect can falsely be attributed to the intervention, leading to an overestimation of effect, whilst in fact, it is the reflection of the normal disease course or other influences.

Furthermore, the included studies provided little information on the actual delivery of the intervention. As a consequence, it remains unclear whether or not the inconsistency of effects found is due to implementation errors.

### **Recommendations for future research**

For future evaluations, outcomes should be chosen related to the goal of the intervention. Quality of life, although the ultimate goal of palliative care, might be a rather distal outcome measure and difficult to modify in this patient group. Qualitative research can identify which outcomes are most important to patients with end-stage COPD and can increase our understanding of the underlying working mechanisms and what works for whom and under what circumstances. Eventually, consensus on the outcome sets to be used is needed in order to compare different interventions and to be able to conduct meta-analyses. Our review revealed a striking difference between the results of quantitative and qualitative studies included. This may be due to the different focus of these two methods. Qualitative research mainly aims to examine the experiences of individuals. and not health effects. In general, additional care or attention from a professional will result in a more positive patient evaluation. That being said, the added value of palliative care interventions in COPD may just be to improve those subjective experiences of individuals in their final stage of the disease. Therefore, we argue that the discrepancy found between the quantitative and qualitative results advocates for a reconsideration of research outcome choices. Hence, we should consider what can most significantly impact the patients' well-being and experience, and not solely focus on health effect parameters. Additionally, we were surprised to find so few outcomes at informal caregiver and professional level. We recommend to include outcomes such as informal caregiver burden and professional's self-efficacy, to acquire knowledge on how informal caregivers can be supported and how professionals can be equipped with the necessary skills. Next, we recommend that future research includes comprehensive process evaluations to unravel requirements for successful implementation and to explore implementation strategies that enhance adoption of new care practices. Various validated tools can be used for this purpose, such as the TIDieR checklist for reporting of intervention characteristics and monitoring intervention fidelity.<sup>62</sup> Also, the Measurement Instrument for Determinants of Innovations framework and Context and Implementation of Complex Interventions framework have been previously used in the palliative care research field and can be used in future studies to measure implementation determinants and contextual factors. 63, 64

## **Strengths and limitations**

To our knowledge, this is the first study reviewing all evidence on the effectiveness and implementation of palliative care interventions in COPD. Since we did not exclude studies based on design or quality, we were able to use all available information in literature in order to give a broad overview. We used a comprehensive and broad search strategy across multiple databases. Study selection, quality assessment and data extraction were conducted by two

authors independently. Implementation outcomes and barriers and facilitators to implementation were categorized using well-established operationalizations.

This systematic review also has some limitations. Although we used a broad search strategy across databases, we included articles only if the authors referred to the intervention as "palliative". This allowed us to use a clear and objective criterion, as there are no fixed criteria which characteristics an intervention must have in order to be labelled as palliative care, nor which patients with COPD should be labelled as "palliative patients". As a consequence, we disregarded interventions targeting patients with severe COPD, but were not referred to as palliative. This may have resulted in the exclusion of relevant interventions with similar intervention characteristics. Due to poor reporting and inconsistent terminology used across studies, categorization of characteristics, implementation outcomes and barriers and facilitators was sometimes difficult. Since all study designs were included, there was high methodological variation between studies and variation in risk of bias. Also, there was heterogeneity in used measurement instruments. For these reasons, the results of the synthesized evidence have to be interpreted with caution.

## **Conclusions**

Although the relevance of palliative care interventions for patients with COPD and their informal caregivers has been widely acknowledged, this study found that little high-quality evidence is available on the effectiveness and implementation of palliative care interventions in COPD-care. There is a need for well-conducted controlled effectiveness studies of sufficient power to reach definite conclusions, and that also explore which characteristics of palliative care complex interventions in COPD are especially effective and for whom. Finally, with clearer results, its implementation should be facilitated and documented with adequate process evaluations using standardized methodologies.

#### Acknowledgements

The authors would like to thank Jan W. Schoones, information specialist at the Walaeus Library of the Leiden University Medical Centre, for assisting in developing and conducting the search strategy for this systematic review.

### **Author contributions**

J.B. and R.K. designed the protocol; J.B., J.S. and A.H. performed the study selection; J.B., A.H., R.K., D.J. and Y.E. extracted data; J.B. and A.H. appraised study quality; J.B., R.K. and A.H. performed data analysis and interpretation; J.B. wrote the first draft; All authors contributed to critical revision and agreed with the final manuscript.

### Data management and sharing

All relevant data are within the manuscript. Any other data are available upon request from the corresponding author.

Effectiveness and implementation of palliative care interventions

#### **Declaration of conflicting interests**

The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.

#### **Funding**

The authors disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was financed by The Netherlands Organization for Health Research and Development (ZonMw).

## References

- 1. WHO. Fact Sheet Top 10 global causes of deaths, 2016, http://www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death (accessed 2018-09-04).
- Habraken JM, ter Riet G, Gore JM, et al. Health-related quality of life in end-stage COPD and lung cancer patients. *J Pain Symptom Manage* 2009; 37: 973-981. 2009/04/28. DOI: 10.1016/j. jpainsymman.2008.07.010.
- 3. WHO. Definition Palliative care, http://www.who.int/cancer/palliative/definition/en/ (2002).
- 4. Kavalieratos D, Corbelli J, Zhang D, et al. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis. *Jama* 2016; 316: 2104-2114. 2016/11/29. DOI: 10.1001/jama.2016.16840.
- 5. Carlucci A, Guerrieri A and Nava S. Palliative care in COPD patients: is it only an end-of-life issue? *European respiratory review : an official journal of the European Respiratory Society* 2012; 21: 347-354. 2012/12/04. DOI: 10.1183/09059180.00001512.
- 6. Janssen DJ, Spruit MA, Uszko-Lencer NH, et al. Symptoms, comorbidities, and health care in advanced chronic obstructive pulmonary disease or chronic heart failure. *J Palliat Med* 2011; 14: 735-743. 2011/04/23. DOI: 10.1089/jpm.2010.0479.
- 7. Cohen J, Beernaert K, Van den Block L, et al. Differences in place of death between lung cancer and COPD patients: a 14-country study using death certificate data. *NPJ Prim Care Respir Med* 2017; 27: 14. 2017/03/05. DOI: 10.1038/s41533-017-0017-y.
- 8. Fried TR, Bradley EH, O'Leary JR, et al. Unmet desire for caregiver-patient communication and increased caregiver burden. *J Am Geriatr Soc* 2005; 53: 59-65. 2005/01/26. DOI: 10.1111/j.1532-5415.2005.53011.x.
- 9. Tavares N, Jarrett N, Hunt K, et al. Palliative and end-of-life care conversations in COPD: a systematic literature review. *ERJ Open Res* 2017; 3 2017/05/04. DOI: 10.1183/23120541.00068-2016.
- 10. Maddocks M, Lovell N, Booth S, et al. Palliative care and management of troublesome symptoms for people with chronic obstructive pulmonary disease. *Lancet* 2017; 390: 988-1002. DOI: S0140-6736(17)32127-X [pii];10.1016/S0140-6736(17)32127-X [doi].
- 11. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. *Am | Respir Crit Care Med* 2008; 177: 912-927. 2008/04/09. DOI: 10.1164/rccm.200605-587ST.
- 12. IKNL/Palliactief. Netherlands Quality Framework for Palliative Care. 2017.
- 13. Phongtankuel V, Meador L, Adelman RD, et al. Multicomponent Palliative Care Interventions in Advanced Chronic Diseases: A Systematic Review. *Am J Hosp Palliat Care* 2018; 35: 173-183. 2016/01/01. DOI: 10.1177/1049909116674669.
- 14. Brighton LJ, Miller S, Farquhar M, et al. Holistic services for people with advanced disease and chronic breathlessness: a systematic review and meta-analysis. *Thorax* 2019; 74: 270-281. 2018/12/01. DOI: 10.1136/thoraxjnl-2018-211589.

- 15. Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. *The Cochrane database of systematic reviews* 2008: Cd005623. 2008/04/22. DOI: 10.1002/14651858.CD005623.pub2.
- 16. Jabbarian LJ, Zwakman M, van der Heide A, et al. Advance care planning for patients with chronic respiratory diseases: a systematic review of preferences and practices. *Thorax* 2018; 73: 222-230. DOI: thoraxjnl-2016-209806 [pii]; 10.1136/thoraxjnl-2016-209806 [doi].
- 17. Ekström M, Nilsson F, Abernethy AA, et al. Effects of opioids on breathlessness and exercise capacity in chronic obstructive pulmonary disease. A systematic review. *Annals of the American Thoracic Society* 2015; 12: 1079-1092. 2015/03/25. DOI: 10.1513/AnnalsATS.201501-034OC.
- 18. Disler RT, Currow DC, Phillips JL, et al. Interventions to support a palliative care approach in patients with chronic obstructive pulmonary disease: an integrative review. *Int J Nurs Stud* 2012; 49: 1443-1458. 2012/03/13. DOI: 10.1016/j.ijnurstu.2012.02.004.
- 19. Craig P, Dieppe P, Macintyre S, et al. Developing and evaluating complex interventions: the new Medical Research Council guidance. *BMJ (Clinical research ed)* 2008; 337: a1655. 2008/10/01. DOI: 10.1136/bmj.a1655.
- 20. Hong QN PP, Fàbregues S, Bartlett G, Boardman F, Cargo M, Dagenais P, Gagnon M-P, Griffiths F, Nicolau B, O'Cathain A, Rousseau M-C, Vedel I. . Mixed Methods Appraisal Tool (MMAT), version 2018. *Registration of Copyright (#1148552), Canadian Intellectual Property Office, Industry Canada* 2018.
- 21. Reeves BC DJ, Higgins JPT, Shea B, Tugwell P, Wells GA. Chapter 24: Including non-randomized studies on intervention effects. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). . Cochrane Handbook for Systematic Reviews of Interventions version 60 (updated July 2019) Cochrane, 2019 Available from www.trainingcochraneorg/handbook.
- *Clinical Practice Guidelines for Quality Palliative Care, Third edition.* 2013. National Consensus Project for Quality Palliative Care.
- 23. Quality standard for end of life care for adults. Issued: August 2011 last modified: October 2013. 2013. National Institute for Health and Care Excellence.
- 24. Pope C, Ziebland S and Mays N. Qualitative research in health care. Analysing qualitative data. *BMJ (Clinical research ed)* 2000; 320: 114-116. 2000/01/22. DOI: 10.1136/bmj.320.7227.114.
- 25. Proctor E, Silmere H, Raghavan R, et al. Outcomes for implementation research: conceptual distinctions, measurement challenges, and research agenda. *Administration and policy in mental health* 2011; 38: 65-76. 2010/10/20. DOI: 10.1007/s10488-010-0319-7.
- 26. Fleuren MA, Paulussen TG, Van Dommelen P, et al. Towards a measurement instrument for determinants of innovations. *International journal for quality in health care: journal of the International Society for Quality in Health Care* 2014; 26: 501-510. 2014/06/22. DOI: 10.1093/intqhc/mzu060.
- 27. Damschroder LJ, Aron DC, Keith RE, et al. Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science. *Implement Sci* 2009; 4: 50. 2009/08/12. DOI: 10.1186/1748-5908-4-50.

- 28. Aiken LS, Butner J, Lockhart CA, et al. Outcome evaluation of a randomized trial of the PhoenixCare intervention: program of case management and coordinated care for the seriously chronically ill. *J Palliat Med* 2006; 9: 111-126. DOI: 10.1089/jpm.2006.9.111 [doi].
- 29. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with advanced disease and refractory breathlessness: a randomised controlled trial. *Lancet Respir Med* 2014; 2: 979-987. DOI: S2213-2600(14)70226-7 [pii];10.1016/S2213-2600(14)70226-7 [doi].
- 30. Farquhar MC, Prevost AT, McCrone P, et al. The clinical and cost effectiveness of a Breathlessness Intervention Service for patients with advanced non-malignant disease and their informal carers: mixed findings of a mixed method randomised controlled trial. *Trials* 2016; 17: 185. DOI: 10.1186/s13063-016-1304-6 [doi];10.1186/s13063-016-1304-6 [pii].
- 31. Duenk RG, Verhagen C, Bronkhorst EM, et al. Proactive palliative care for patients with COPD (PROLONG): a pragmatic cluster controlled trial. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2795-2806. DOI: 10.2147/COPD.S141974 [doi];copd-12-2795 [pii].
- 32. Rabow MW, Dibble SL, Pantilat SZ, et al. The comprehensive care team: a controlled trial of outpatient palliative medicine consultation. *Arch Intern Med* 2004; 164: 83-91. DOI: 10.1001/archinte.164.1.83 [doi];164/1/83 [pii].
- 33. Rabow MW, Petersen J, Schanche K, et al. The comprehensive care team: a description of a controlled trial of care at the beginning of the end of life. *J Palliat Med* 2003; 6: 489-499. DOI: 10.1089/109662103322144862 [doi].
- 34. Edes TE, Lindbloom EJ, Deal JL, et al. Improving care at lower cost for end-stage heart and lung disease: integrating end of life planning with home care. *Mo Med* 2006; 103: 146-151.
- 35. Rocker GM and Verma JY. 'INSPIRED' COPD Outreach Program: doing the right things right. *Clinical and investigative medicine Medecine clinique et experimentale* 2014; 37: E311-319. 2014/10/06.
- 36. Iupati SP and Ensor BR. Do community hospice programmes reduce hospitalisation rate in patients with advanced chronic obstructive pulmonary disease? *Intern Med J* 2016; 46: 295-300. DOI: 10.1111/imj.12947 [doi].
- 37. Long MB, Bekelman DB and Make B. Improving Quality of Life in Chronic Obstructive Pulmonary Disease by Integrating Palliative Approaches to Dyspnea, Anxiety, and Depression. *Journal of Hospice & Palliative Nursing* 2014; 16: 514-520.
- 38. Smallwood N, Thompson M, Warrender-Sparkes M, et al. Integrated respiratory and palliative care may improve outcomes in advanced lung disease. *ERJ Open Res* 2018; 4. DOI: 10.1183/23120541.00102-2017 [doi];00102-2017 [pii].
- 39. Steinel JA and Madigan EA. Resource utilization in home health chronic obstructive pulmonary disease management. *Outcomes Manag* 2003; 7: 23-27.
- 40. van Dam van Isselt EF, Spruit M, Groenewegen-Sipkema KH, et al. Geriatric rehabilitation for patients with advanced chronic obstructive pulmonary disease: a naturalistic prospective

- cohort study on feasibility and course of health status. *Chronic respiratory disease* 2014; 11: 111-119, 2014/04/15, DOI: 10.1177/1479972314529674.
- 41. Rocker GM, Amar C, Laframboise WL, et al. Spreading improvements for advanced COPD care through a Canadian Collaborative. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 2157-2164. DOI: 10.2147/COPD.S140043 [doi];copd-12-2157 [pii].
- 42. Booth S, Farquhar M, Gysels M, et al. The impact of a breathlessness intervention service (BIS) on the lives of patients with intractable dyspnea: a qualitative phase 1 study. *Palliat Support Care* 2006: 4: 287-293. 2006/10/28.
- 43. Reilly CC, Bausewein C, Pannell C, et al. Patients' experiences of a new integrated breathlessness support service for patients with refractory breathlessness: Results of a postal survey. *Palliat Med* 2016; 30: 313-322. 2015/08/28. DOI: 10.1177/0269216315600103.
- 44. Johnston B, Coole C and Jay NM. An end-of-life care nurse service for people with COPD and heart failure: stakeholders' experiences. *Int J Palliat Nurs* 2016; 22: 549-559. DOI: 10.12968/ijpn.2016.22.11.549 [doi].
- 45. Rabow MW, Schanche K, Petersen J, et al. Patient perceptions of an outpatient palliative care intervention: "It had been on my mind before, but I did not know how to start talking about death...". *Journal of Pain and Symptom Management* 2003; 26: 1010-1015.
- 46. Bove DG, Jellington MO, Lavesen M, et al. Assigned nurses and a professional relationship: a qualitative study of COPD patients' perspective on a new palliative outpatient structure named CAPTAIN. *BMC Palliat Care* 2019; 18: 24. 2019/03/04. DOI: 10.1186/s12904-019-0410-0.
- 47. Bove DG, Lavesen M, Jellington MO, et al. First year experiences with a palliative out-patients structure for patients with COPD: a qualitative study of health professionals' expectations and experiences. *BMC Palliative Care* 2018; 17.
- 48. Verma JY, Amar C, Sibbald S, et al. Improving care for advanced COPD through practice change: Experiences of participation in a Canadian spread collaborative. *Chron Respir Dis* 2017: 1479972317712720. DOI: 10.1177/1479972317712720 [doi].
- 49. Farquhar MC, Higginson IJ, Fagan P, et al. The feasibility of a single-blinded fast-track pragmatic randomised controlled trial of a complex intervention for breathlessness in advanced disease. *BMC Palliat Care* 2009; 8: 9. DOI: 1472-684X-8-9 [pii];10.1186/1472-684X-8-9 [doi].
- 50. Farquhar M, Higginson IJ, Fagan P, et al. Results of a pilot investigation into a complex intervention for breathlessness in advanced chronic obstructive pulmonary disease (COPD): brief report. *Palliat Support Care* 2010; 8: 143-149. DOI: S1478951509990897 [pii];10.1017/S1478951509990897 [doi].
- 51. Gillis D, Demmons J and Rocker G. Expanding The INSPIRED COPD Outreach Program to the emergency department: a feasibility assessment. *Int J Chron Obstruct Pulmon Dis* 2017; 12: 1597-1604. 2017/06/16. DOI: 10.2147/copd.s136183.
- 52. Buckingham S, Kendall M, Ferguson S, et al. HELPing older people with very severe chronic obstructive pulmonary disease (HELP-COPD): mixed-method feasibility pilot randomised

- controlled trial of a novel intervention. *NPJ Prim Care Respir Med* 2015; 25: 15020. DOI: npjpcrm201520 [pii];10.1038/npjpcrm.2015.20 [doi].
- 53. Horton R, Rocker G, Dale A, et al. Implementing a palliative care trial in advanced COPD: a feasibility assessment (the COPD IMPACT study). *J Palliat Med* 2013; 16: 67-73. DOI: 10.1089/jpm.2012.0285 [doi].
- 54. Qian MYY, Politis J, Thompson M, et al. Individualized breathlessness interventions may improve outcomes in patients with advanced COPD. *Respirology* 2018. DOI: 10.1111/ resp.13324 [doi].
- 55. Scheerens C, Pype P, Van Cauwenberg J, et al. Early Integrated Palliative Home Care and Standard Care for End-Stage COPD (EPIC): A Phase II Pilot RCT Testing Feasibility, Acceptability, and Effectiveness. *J Pain Symptom Manage* 2020; 59: 206-224.e207. 2019/10/13. DOI: 10.1016/j.jpainsymman.2019.09.012.
- Vitacca M, Comini L, Tabaglio E, et al. Tele-Assisted Palliative Homecare for Advanced Chronic Obstructive Pulmonary Disease: A Feasibility Study. *J Palliat Med* 2019; 22: 173-178. 2018/09/27. DOI: 10.1089/jpm.2018.0321.
- 57. Janssens JP, Weber C, Herrmann FR, et al. Can Early Introduction of Palliative Care Limit Intensive Care, Emergency and Hospital Admissions in Patients with Severe Chronic Obstructive Pulmonary Disease? A Pilot Randomized Study. *Respiration* 2019; 97: 406-415. DOI: 10.1159/000495312.
- 58. Lockhart CA, Volk-Craft BE, Hamilton G, et al. The PhoenixCare Program. *J Palliat Med* 2003; 6: 1001-1012. 2004/01/22. DOI: 10.1089/109662103322654929.
- 59. Datla S, Verberkt CA, Hoye A, et al. Multi-disciplinary palliative care is effective in people with symptomatic heart failure: A systematic review and narrative synthesis. *Palliat Med* 2019; 33: 1003-1016. 2019/07/17. DOI: 10.1177/0269216319859148.
- 60. Mannino DM and Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. *Lancet* 2007; 370: 765-773. 2007/09/04. DOI: 10.1016/s0140-6736(07)61380-4.
- 61. Landers A, Wiseman R, Pitama S, et al. Patient perceptions of severe COPD and transitions towards death: a qualitative study identifying milestones and developing key opportunities. *NPJ Prim Care Respir Med* 2015; 25: 15043. 2015/07/15. DOI: 10.1038/npjpcrm.2015.43.
- 62. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ (Clinical research ed)* 2014; 348: g1687. 2014/03/13. DOI: 10.1136/bmj.g1687.
- 63. Verberne LM, Kars MC, Schepers SA, et al. Barriers and facilitators to the implementation of a paediatric palliative care team. *BMC Palliat Care* 2018; 17: 23. 2018/02/13. DOI: 10.1186/s12904-018-0274-8.
- 64. Pfadenhauer LM, Gerhardus A, Mozygemba K, et al. Making sense of complexity in context and implementation: the Context and Implementation of Complex Interventions (CICI) framework. *Implement Sci* 2017; 12: 21. 2017/02/17. DOI: 10.1186/s13012-017-0552-5

# **Supplementary material**

Table S1. Example search strategy for PubMed

("advanced COPD"[tiab] OR "end-stage COPD"[tiab] OR advanced chronic obstructive\*[tiab] OR end-stage chronic obstructive\*[tiab]

OR

(("Pulmonary Disease, Chronic Obstructive" [Mesh] OR "chronic obstructive pulmonary disease" [tw] OR "COPD" [tw] OR "COPD\* [tw] OR "COAD" [tw] OR "Chronic Obstructive Airway Disease" [tw] OR "Chronic Obstructive Lung Disease" [tw] OR "Chronic Airflow Obstructions" [tw] OR "Chronic Airflow Obstructions" [tw] OR "chronic bronchitis" [tw] OR "pulmonary emphysema" [tw] OR "Pulmonary Emphysemas" [tw] OR "Focal Emphysema" [tw] OR "Panacinar Emphysema" [tw] OR "Panlobular Emphysema" [tw] OR "Centriacinar Emphysema" [tw] OR "Centrilobular Emphysema" [tw])

AND

("Palliative Care"[Mesh] OR "palliative care"[tw] OR "palliative care interventions"[tw] OR "palliative care interventions"[tw] OR "Palliative Therapy"[tw] OR "Palliative Treatment"[tw] OR "Palliative Treatments"[tw] OR "Palliative Surgery"[tw] OR "Palliative therapy"[tw] OR "palliative phase"[tw] OR "palliative phases"[tw] OR "Palliative Medicine"[mesh] OR "Terminal Care"[Mesh:noexp] OR "Hospice Care"[Mesh] OR "Resuscitation Orders"[mesh] OR "Terminal Care"[tw] OR "Hospice Care"[tw] OR "Hospice Programs"[tw] OR "Hospice Programs"[tw] OR "Hospice Programs"[tw] OR "Bereavement Care"[tw] OR "End-of-Life Care"[tw] OR "Life Care End"[tw] OR "supportive care"[tw] OR "terminally ill"[tiab] OR "Terminally Ill"[Mesh] OR "advanced illness"[tiab] OR "advanced disease"[tiab] OR "Death"[mesh:noexp] OR "dying loved one"[tiab] OR "dying patient"[tiab] OR "dying patients"[tiab] OR "dying people"[tiab] OR "dying person"[tiab] OR "dying"[tiab] OR "last year of life"[tiab] OR "end-of-life"[tiab] OR "death and dying"[tiab] OR "limited life expectancies"[tiab] OR "limited life expectancy"[tiab] OR "limited life spans"[tiab] OR "limited life spans"[tiab] OR "limited life spans"[tiab] OR "frail Elderly"[Mesh])))

### **Table S2.** Operationalizations of palliative care domains

Chapter 3

Identification	Early and proactive identification of the palliative care phase.
Advance care planning	A continuous and dynamic process of discussions on life goals and choices, and on which care is an appropriate fit, now and in the future.
Individual care plan	A document which is kept with the patient in which the agreements focusing on physical, psychological, social and spiritual well-being are recorded.
Informal caregiver support	Support to a family member who plays an important role in caring for the patient and is actively involved in this.
Interdisciplinary care	Involvement of several disciplines working together in an interdisciplinary team.
Coordination	People approaching the end of life receive consistent care that is coordinated effectively across all relevant settings and services at any time of day or night, and delivered by practitioners who are aware of the person's current medical condition, care plan and preferences.
Physical dimension	Assessment and management of physical needs.
Psychological dimension	Assessment and management of psychological needs.
Social dimension	Assessment and management of social needs.
Spiritual dimension	Assessment and management of spiritual, religious and existential needs.
End-of-life care	Patients at the end of life are identified at an early stage. The individual care plan is updated accordingly, or the End-of-life care pathway is started.
Bereavement support	People closely affected by a death are offered bereavement support.

Effectiveness and implementation of palliative care interventions

Table S3. Operationalizations of implementation outcomes

Acceptability	The perception among implementation stakeholders that a given treatment, service, practice, or innovation is agreeable, palatable, or satisfactory.
Adoption	The intention, initial decision, or action to try or employ an innovation.
Appropriateness	The perceived fit, relevance, or compatibility of the innovation for a given practice setting, provider, or consumer.
Costs	Implementation costs.
Feasibility	The extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting.
Fidelity	The degree to which an intervention was implemented as it was prescribed in the original protocol or as it was intended by the program developers.
Penetration	Integration of practice within a setting.
Sustainability	The extent to which a newly implemented treatment is maintained or institutionalized.

19. Awareness of content of

20. Previous experience with

innovation

similar innovation

**Table S4.** Codebook for extraction of determinants of implementation

Codes from the Measurement Instrument for Determinants of Innovations (MIDI)(1). Inductively added codes based on the Consolidated Framework for Implementation Research (CFIR)(2) in blue and other inductively added codes in pink.

Determinants associated with	the innovation								
1. Procedural clarity	Description: Extent to which the innovation is described in clear steps / procedures.								
2. Correctness	Description: Degree to which the innovation is based on factually correct knowledge.								
3. Completeness	Description: Degree to which the activities described in the innovation are complete.								
4. Complexity	Description: Degree to which implementation of the innovation is complex.								
5. Compatibility	Description: Degree to which the innovation is compatible with th values and working method in place.								
6. Observability	Description: Visibility of the outcomes for the user, for example whether the outcomes of a particular treatment are clear to the user.								
7. Relevance for patient	Description: Degree to which the user believes the innovation is relevant for his/her patient.								
8. Accessibility	Description: Degree to which the innovation is accessible for the patient.								
Determinants associated with	the adopting person (user)								
9. Personal benefits/drawback	S Description: Degree to which using the innovation has advantages or disadvantages for the users themselves.								
10. Outcome expectations	Description: Perceived probability and importance of achieving the patient objectives as intended by the innovation.								
11. Professional obligation	Description: Degree to which the innovation fits in with the tasks fo which the user feels responsible when doing his/her work.								
12. Patient satisfaction	Description: Degree to which the user expects patients to be satisfied with the innovation.								
13. Patient cooperation	Description: Degree to which the user expects patients to cooperate with the innovation.								
14. Social support	Description: Support experienced or expected by the user from important social referents relating to the use of the innovation (for example from colleagues, other professionals they work with, heads of department or management).								
15. Descriptive norm	Description: Colleagues' observed behaviour; degree to which colleagues use the innovation.								
16. Subjective norm	Description: The influence of important others on the use of the innovation.								
17. Self-efficacy	Description: Degree to which the user believes he or she is able to implement the activities involved in the innovation.								
18. Knowledge	Description: Degree to which the user has the knowledge needed to use the innovation.								
10 Assessment of content of	Description, Degree to which the year has learnt about the content								

of the innovation.

current innovation.

Description: Degree to which the user has learnt about the content

Description: Degree to which the experience of a user with a similar

innovation in the past has influence on implementation of the

22. Tension for change	Description: Degree to which stakeholders perceive the current situation as intolerable or needing change.								
23. Disease specific characteristics	Description: Degree to which disease specific characteristics hampers implementation. For example, the unpredictable disease trajectory which makes predicting the palliative phase difficult.								
Determinants associated with th	ne organisation								
24. Formal ratification by management	Description: Formal ratification of the innovation by management, for example by including the use of the innovation in policy documents.								
25. Replacement when staff leave	Description: Replacement of staff leaving the organization.								
26. Staff capacity	Description: Adequate staffing in the department or in the organisation where the innovation is being used.								
27. Financial resources	Description: Availability of financial resources needed to use the innovation.								
28. Time available	Description: Amount of time available to use the innovation.								
29. Material resources and facilities	Description: Presence of materials and other resources or facilities necessary for the use of the innovation as intended (such as equipment, materials or space).								
30. Coordinator	Description: The presence of one or more persons responsible for coordinating the implementation of the innovation in the organisation.								
31. Unsettled organisation	Description: Degree to which there are other changes in progress (organisational or otherwise) that represent obstacles to the process of implementing the innovation, such as reorganisations, mergers, cuts, staffing changes or the simultaneous implementation of different innovations.								
32. Information accessible about use of innovation	Description: Accessibility of information about the use of the innovation.								
33. Performance feedback	Description: Feedback to the user about progress with the innovation process.								
34. Leadership engagement	Description: Commitment, involvement, and accountability of leaders and managers with the implementation of the innovation.								
35. External policy & Incentives	Description: A broad construct that includes external strategies to spread innovations including policy and regulations (governmental or other central entity), external mandates, recommendations and guidelines, pay-for-performance, collaboratives, and public or benchmark reporting.								
Determinants associated with th	ne socio-political context								
36. Legislation and regulations	Description: Degree to which the innovation fits in with existing legislation and regulations established by the competent authorities (examples being financial structures, or substantive legislation and supervision from the Dutch Health Care								

Inspectorate or the Dutch Care Authority).

Effectiveness and implementation of palliative care interventions

led to implementation and use of innovation.

Description: Degree to which publicity and marketing activities have

Chapter 3

21. Publicity

 Table S5. Quality assessment of included studies.

Reference	Study design		eening stions		ualita	ative					tative ed co	ntrolled trials			uanti domiz		non-		4. Q	uanti	tative	e desc	riptiv	e 5. N	∕lixed	meth	ods		Score
		S1	S2	1.1	1.2	1.3	1.4	1.5	2.1	2.2	2.3	2.4	2.5	3.1	3.2	3.3	3.4	3.5	4.1	4.2	4.3	4.4	4.5	5.1	5.2	5.3	5.4	5.5	
Aiken (2006)	RCT	Υ	Υ						Υ	Υ	N	Υ	Y																_ ****
Lockhart (2003)	Unclear	Ν	Ν																										*
Bove (2018)	Q	Υ	Υ	Υ	Υ	Υ	Υ	Υ																					****
Bove (2019)	Q	Υ	Υ	Υ	Υ	Υ	Υ	Υ																					****
Buckingham (2015)	RCT +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N	N	N	Υ											Υ	Υ	Υ	Υ	N	***
Duenk (2017)	CCT	Υ	Υ											Υ	Υ	Υ	Υ	U											****
Edes (2006)	ВА	Υ	Υ											Ν	Υ	Υ	Ν	U											**
Farquhar (2016)	RCT +Q	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	U											Υ	Υ	Υ	Υ	Υ	****
Farquhar (2009)	RCT +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	U	Ν	U	Υ	U	Υ	Υ	U											Υ	Ν	Ν	Ν	Ν	**
Farquhar (2010)	BA +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	U	Υ	U						Υ	Υ	Υ	Ν	U						Υ	Υ	Υ	Υ	Υ	***
Booth (2006)	Q	Υ	Υ	Υ	Υ	Υ	Υ	Υ																					****
Higginson (2014)	RCT	Υ	Υ						Υ	Υ	Υ	Υ	U																***
Reilly (2016)	Q	Υ	Υ	Ν	Ν	Υ	Υ	Υ																					***
Horton (2013)	BA (pilot/feasibility)	Υ	Υ											Υ	Υ	Ν	Ν	Υ											***
Janssens (2019)	RCT (pilot/feasibility)	Υ	Υ						Υ	Υ	Υ	U	U																***
lupati (2016)	BA	Υ	Υ											Υ	Υ	Υ	Ν	U											***
Johnston (2016)	Q	Υ	Υ	Υ	Υ	Υ	Υ	Υ																					****
Long (2014)	BA +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	Υ	Ν	Υ						Ν	Υ	Υ	Ν	Υ						Υ	Υ	Υ	Ν	Υ	***
Qian (2018)	BA +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	Υ	Υ	Υ						Υ	Υ	Υ	Ν	U						Υ	Ν	Ν	Υ	Υ	***
Rabow (2003a) / Rabow (2004)	CCT +Q	Υ	Υ	Υ	U	Υ	Υ	N						Υ	Υ	Υ	Υ	N						Υ	N	Υ	Υ	N	***
Rabow (2003b)	Q	Υ	Υ	Υ	U	Υ	Υ	Ν																					***
Rocker (2014)	BA +Q	Ν	U																										*
Gillis (2017)	BA +Q (pilot/feasibility)	Υ	Υ	Υ	U	U	Ν	Ν						Υ	Υ	Υ	Ν	Υ						Υ	Ν	Ν	U	Ν	**
Rocker (2017)	BA +Q	Υ	Υ	Ν	Ν	U	Ν	U						U	U	U	U	U						Υ	Ν	U	Ν	Ν	*
Verma (2017)	Non-comparative +Q	Υ	Υ	Υ	Υ	Υ	Ν	Υ											Υ	U	Ν	Ν	Ν	Υ	Ν	Ν	Ν	Ν	**
Scheerens (2018)	RCT +Q (pilot/feasibility)	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	Υ	N	Υ											Υ	Υ	Υ	U	Υ	***
Smallwood (2018)	BA	Υ	Υ											Υ	Υ	Υ	N	Υ											****
Steinel (2003)	BA	Υ	Υ											Ν	Υ	U	Ν	U											*
Van Dam (2014)	ВА	Υ	N+Y	,										Υ	N+Y	Υ	Ν	U											**
Vitacca (2019)	BA +Q (pilot/feasibility)	Υ	Υ											Υ	Υ	Υ	Ν	Υ											***

Chapter 3

**Abbreviations:** RCT = Randomized controlled trial; BA = Before-and-after study;

CCT = Non-randomized clinical controlled trial, Q = Qualitative study design,

Y = Yes, N = No, N+Y = for first part of research question answer No,

for second part answer Yes, U = Can't tell.

<sup>+</sup>Q = Qualitative data additional to quantitative study design,

**Table S6.** Barriers and facilitators for implementation (determinants) for referrers, providers and patients.

User type	Determinant	References
Referrer		
	Relevance for patient	Booth (2006)
	The second secon	Buckingham (2015)
		Rabow (2003a)
	Awareness of content of innovation	Lockhart (2003)
	milovation	Gillis (2017)
		Johnston (2016)
	Disease characteristics	Rocker (2017)
	Disease characteristics	Johnston (2016)
		Rabow (2003a)
	Publicity	Lockhart (2003)
	Professional obligation	Lockhart (2003)
	Patient satisfaction	Booth (2006)
	Correctness	Booth (2006)
	Personal benefits/drawbacks	Booth (2006)
		Rabow (2003a)
	Compatibility	Booth (2006)
		Gillis (2017)
	Tension for change	Booth (2006)
	S	Buckingham (2015)
	Time available	Gillis (2017)
	Complexity	Gillis (2017)
	Completeness	Johnston (2016)
	Procedural clarity	Johnston (2016)
	Financial resources	Rabow (2003a)
Provider		
	Time available	Gillis (2017)
		Rocker (2017)
		Verma (2017)
		Johnston (2016)
		Rabow (2003a)
		Scheerens (2019)
	Staff capacity	Lockhart (2003)
		Horton (2013)
		Rabow (2003a)
	Compatibility	Buckingham (2015)
		Verma (2017)
		Johnston (2016)
	Financial resources	Verma (2017)
		Horton (2013)
		Rabow (2003a)

User type	Determinant	References							
	Material resources and facilities	Rabow (2003a)							
		Scheerens (2019)							
	Knowledge	Lockhart (2003)							
		Rocker (2017)							
	Correctness	Buckingham (2015)							
		Scheerens (2019)							
	Information accessible about use of innovation	Buckingham (2015)							
		Verma (2017)							
	Leadership engagement	Rocker (2017)							
		Verma (2017)							
	External policy & Incentives	Verma (2017)							
	Completeness	Verma (2017)							
	Performance feedback	Verma (2017)							
	Complexity	Verma (2017)							
	Formal ratification by management	Verma (2017)							
	Tension for change	Horton (2013)							
	Unsettled organization	Rabow (2003a)							
	Publicity	Rabow (2003a)							
Patient									
	Accessibility	Buckingham (2015)							
		Rocker (2017)							
		Horton (2013)							
		Long (2014)							
		Rabow (2003a)							
	Relevance for patients	Buckingham (2015)							
	Personal benefits/drawbacks	Buckingham (2015)							
	Previous experience with similar innovation	Buckingham (2015)							
	Compatibility	Buckingham (2015)							
	Financial resources	Long (2014)							
	the state of the s								

Unsettled organization

Effectiveness and implementation of palliative care interventions

Rabow (2003a)

Chapter 3